Liberty

Short Description

Study of UBEnimex in patients with PAH WHO Group 1

Liberty: A phase 2, randomized, double-blind, placebo-controlled study of UBEnimex in patients with PAH WHO Group 1.  Ubenimex is an inhibitor of both leukotriene A4 hydrolase and aminopeptidase. It has the potential to be a disease modifying for PAH via a novel mechanism of action that is anti-inflammatory and anti-proliferative rather than exclusively vasodilatory.

• Age 18 to 75
• PAH WHO Group I – idiopathic, heritable, drug/toxin induced or associated with PAH specifically CTD or Congenital heart disease.
• WHO/NYHA FC of II or III
• Right heart cath as screening with a mPAP ≥ 25 mmHg, PCWP ≤ 15 mmHg, and PVR ≥ 3.75 woods
• On stable dose of PAH specific therapies – see protocol
• No significant obstruction or restrictive lung disease.

Questions: Call Mary Soltau 303-703-2191 or Rebecca Wimmer 303-715-2275

• Author
• Recent Posts

South Denver Cardiology

Randy Cupps Graduated from Western Colorado University in Gunnison, Colorado, in 1983 with a degree in Physical Education with an emphasis in Exercise Physiology. Randy started his medical career in 1980 as an Emergency Medical Technician (EMT) working on an ambulance and in an emergency room. He then joined South Denver Cardiology in 1986 when it was South Denver Cardiac Rehabilitation as an Exercise Physiologist conducting a wide variety of Graded Exercise Testing on a diverse patient population. Randy continues to keep his EMT current, and he is certified by the American College of Sports Medicine as a Clinical Exercise Physiologist. In 2012 Randy acquired the role of business development, marketing, and physician relations manager at SDCA.

Latest posts by South Denver Cardiology (see all)

• 9 Tips to Reduce Holiday Stress - December 11, 2025
• 6 Tips for Exercising Outdoors with a Heart Condition - May 19, 2025
• Lifestyle Changes That Can Help Manage Arrhythmia - April 30, 2025

Recommend